Turnaround works, but debt still matters
- Biopharma made 86.2% of 2025 revenue, so Grifols is mainly a plasma medicines company.
- Management is cutting cost per liter by scaling Egypt plasma and closing weak U.S. donor centers.
- Debt pressure is lower after the 2026 refinancing, but leverage still limits the story.
- China albumin pricing and a weaker U.S. dollar are the main near-term profit drags.
- The possible U.S. Biopharma IPO could speed debt reduction, but management has not explained the structure.
A cleaner turnaround, not a clean balance sheet
The bull case is that Grifols is finally doing the hard work its balance sheet demanded. It refinanced 2027 maturities, pushed major debt risk out, and keeps improving plasma operations. The Egypt platform is expected to collect about 1 million liters in 2026 and scale to about 3 million liters by 2029. That matters because cheaper plasma can lift margins.
The business demand picture is also solid. Immunoglobulin, the core medicine group, has regained lost U.S. share after the pandemic disruption. Management now expects that franchise to grow around a 6% to 8% CAGR, meaning a yearly growth rate over time.
The bear case has not gone away. Grifols still carries a heavy debt load. Albumin in China faces hard comparisons in the first half of 2026 after 2025 pricing concessions, and a weaker U.S. dollar hurts reported EBITDA. Management also dodged detailed questions on the possible U.S. Biopharma IPO, which leaves a key debt reduction catalyst unclear.
Finn's view fits that mix. Growth is real, valuation is not stretched, but performance and financial health still reflect a company working through past leverage and execution problems.
Plasma in, proteins out
Grifols runs a vertically integrated plasma model. It collects plasma from donors, processes it in factories, and separates it into proteins used as medicines. That separation process is called fractionation.
The key profit lever is cost per liter, or how much it costs to collect each liter of plasma before it becomes medicine. Grifols is moving toward a two-system model: U.S. plasma mainly serves the U.S. market, while Egypt and other non-U.S. sources serve rest-of-world demand. The goal is to stop shipping as much high-cost U.S. plasma into lower-price markets.
Scale helps, but it also raises execution risk. The company had more than 400 plasma collection centers at the end of 2025, then said in Q1 2026 it had closed 29 underperforming U.S. donor centers with some volume moved to better sites. If collections, yields, or donor economics slip, the margin story weakens fast.
Cash also depends on timing. Plasma collected today can take time to become finished product. That means growth can use cash before it shows up as revenue.
The medicines that drive the model
Immunoglobulins
This is the core franchise, led by Gamunex, Xembify, and Biotest Yimmugo in the U.S. Demand is strong, and management expects the franchise to normalize around a 6% to 8% CAGR.
Subcutaneous IG
Subcutaneous IG is taken under the skin instead of through an IV. Xembify has been a major growth driver because it can be easier for some patients to use at home.
Albumin
Albumin is a large plasma protein business, but China is pressuring prices through healthcare cost controls. That makes it a cash generator with a current headwind.
Alpha-1 therapies
Alpha-1 treatments serve patients with a rare protein deficiency that can damage lungs and liver. The SPARTA readout in H2 2026 is a watch item for this franchise.
Prufibry
Prufibry is Grifols' fibrinogen product for Congenital Fibrinogen Deficiency. The company delayed the acquired deficiency path to gather more clinical evidence.
Diagnostics
Diagnostics gives Grifols a smaller, steadier business in blood typing and donor screening. After ending the QuidelOrtho joint business, Grifols is building its own path with the Barcelona-Next Gen platform.
Biopharma carries the company
The mix uses 2025 net revenue from the 2025 Form 20-F. Biopharma is 86.2% of revenue, so changes in immunoglobulin, albumin, and plasma costs matter far more than the smaller units.
What could still break
Debt stays too high
High impact · Medium oddsThe 2026 refinancing removed the near 2027 wall and extended major facilities to the next decade. That lowers near-term danger, but it does not make Grifols low-debt. If EBITDA stalls, leverage can stay too high and keep pressure on the stock.
U.S. Biopharma IPO disappoints
High impact · Medium oddsThe possible IPO of a minority stake in U.S. Biopharma could help debt reduction. The problem is that management has not given key details on valuation, timing, governance, or how proceeds would be used. A weak structure could confuse investors instead of helping them.
China albumin pricing pressure lasts
Medium impact · High oddsAlbumin sales are under pressure in China because of government cost controls. Management said hospital pricing has stabilized, but the first half of 2026 still compares against a higher 2025 price base. A longer price reset would hurt revenue mix and margins.
Egypt scale-up misses
Medium impact · Medium oddsThe Egypt plasma platform is central to lowering cost per liter outside the U.S. Grifols targets about 1 million liters in 2026 and about 3 million liters by 2029. Any collection, quality, or logistics issue would slow the margin plan.
New CIDP drugs take share
Medium impact · Medium oddsSome patients with CIDP use immunoglobulin therapy, which is important to Grifols. Novel FcRn inhibitors could compete for those patients. Management has pushed back by saying some patients are switching back to IG, but the threat is real.
Currency and U.S. policy drag EBITDA
Medium impact · Medium oddsA weaker U.S. dollar hurts Grifols when dollar profits are translated into euros. Management said each cent of U.S. dollar depreciation versus the euro has about a EUR 7 million full-year EBITDA headwind. U.S. IRA Part D redesign is another pressure point.
In one breath
What does Grifols actually do?
Grifols collects human plasma and turns it into medicines. Its main products treat immune disorders, albumin needs, Alpha-1 deficiency, and blood clotting problems.
Why does plasma cost matter so much?
Plasma is the raw material for Grifols' main medicines. If the company collects each liter at a lower cost and processes it well, margins can rise.
Is Grifols still risky because of debt?
Yes. The 2026 refinancing reduced near-term refinancing risk, but the company is still leveraged. Investors should watch leverage, free cash flow, and any proceeds from the possible U.S. Biopharma IPO.
What are the next big catalysts?
The biggest watch items are details on the U.S. Biopharma IPO, Prufibry launch progress, and the SPARTA Alpha-1 clinical readout expected in H2 2026.